Table 2 Clinical Studies with Dextromethorphan
Study | Sample Size | Design | Disease | Results |
|---|---|---|---|---|
Lee PCL et al. Antitussive efficacy dextromethorphan in cough associated with acute upper respiratory in- fection. Journal of Pharmacy and Pharmacology 2000;52:1137-42. | 44 adults | A double-blind, stratified, randomized and parallel group design | URTI's | This study provides very little if any support for clinically significant antitussive activity of a single 30 mg dose of dextromethorphan in patients with cough associated with URTI's |
Parvez L, et al Evaluation of antitussive agents in man. Pulmonary Pharmacology 1996;9(5-6):299-308. | 451 adults | Review of three different studies randomized, double blind, placebo controlled | URTI's | The results establish the sensitivity and robustness of the cough quantization methodology in the objective evaluation of cough treatments |
Pavesi L et al. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest 001;120:1121-8. | 710 adults | Six studies used for the meta-analysis were randomized, double-blind, parallel-group, single-dose, placebo-controlled studies with a 3-h postdose cough evaluation period | URTI's | The results of a meta-analysis show that the antitussive effect of a single dose of dextromethorphan hydrobromide, 30 mg, has been established. |